Therapeutic inhibition of tumour necrosis factor α in patients with heart failure:: cooling an inflamed heart

被引：23

作者：

Henriksen, PA ^{[1
]}

Newby, DE ^{[1
]}

机构：

[1] Univ Edinburgh, Dept Cardiol, Royal Infirm, Edinburgh EH3 9YW, Midlothian, Scotland

来源：

HEART | 2003年 / 89卷 / 01期

基金：

英国惠康基金;

关键词：

D O I：

10.1136/heart.89.1.14

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure is a systemic disorder characterised by tissue hypoxia and secondary organ dysfunction which occurs in response to various myocardial insults that include schaemia, viral infections, and toxins. In addition to maladaptive neurohumoral activation, heart failure is associated with an inflammatory state that appears to have a detrimental effect on cardiac function and prognosis. This has led to the suggestion that anti-inflammatory interventions may have therapeutic potential in the symptomatic and prognostic treatment of patients with heart failure. This review considers the role of inhibition of the cytokine tumour necrosis factor a in the treatment of heart failure.

引用

页码：14 / 18

页数：5

共 47 条

[1] A glossary of circulating cytokines in chronic heart failure
Adamopoulos, S
Parissis, JT
Kremastinos, DT
[J]. EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (05) : 517 - 526
[2] Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
Anker, SD
Ponikowski, PP
Clark, AL
Leyva, F
Rauchhaus, M
Kemp, M
Teixeira, MM
Hellewell, PG
Hooper, J
Poole-Wilson, PA
Coats, AJS
[J]. EUROPEAN HEART JOURNAL, 1999, 20 (09) : 683 - 693
[3] Mechanisms of disease - Nuclear factor-kappa b - A pivotal transcription factor in chronic inflammatory diseases
Barnes, PJ
Larin, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (15) : 1066 - 1071
[4] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
Bathon, JM
Martin, RW
Fleischmann, RM
Tesser, JR
Schiff, MH
Keystone, EC
Genovese, MC
Wasko, MC
Moreland, LW
Weaver, AL
Markenson, J
Finck, BK
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1586 - 1593
[5] Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives
Blam, ME
Stein, RB
Lichtenstein, GR
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (07) : 1977 - 1997
[6] Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure
Bozkurt, B
Torre-Amione, G
Warren, MS
Whitmore, J
Soran, OZ
Feldman, AM
Mann, DL
[J]. CIRCULATION, 2001, 103 (08) : 1044 - 1047
[7] Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats
Bozkurt, B
Kribbs, SB
Clubb, FJ
Michael, LH
Didenko, VV
Hornsby, PJ
Seta, Y
Oral, H
Spinale, FG
Mann, DL
[J]. CIRCULATION, 1998, 97 (14) : 1382 - 1391
[8] Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-α
Bryant, D
Becker, L
Richardson, J
Shelton, J
Franco, F
Peshock, R
Thompson, M
Giroir, B
[J]. CIRCULATION, 1998, 97 (14) : 1375 - 1381
[9] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
Chaudhari, U
Romano, P
Mulcahy, LD
Dooley, LT
Baker, DG
Gottlieb, AB
[J]. LANCET, 2001, 357 (9271) : 1842 - 1847
[10] NITRIC-OXIDE SYNTHASE ACTIVITIES IN HUMAN MYOCARDIUM
DEBELDER, AJ
RADOMSKI, MW
WHY, HJF
RICHARDSON, PJ
BUCKNALL, CA
SALAS, E
MARTIN, JF
MONCADA, S
[J]. LANCET, 1993, 341 (8837) : 84 - 85

← 1 2 3 4 5 →